Wednesday, May 12, 2021

Reviva Pharmaceutical Holdings, Inc. (RVPH) Stock Prices Skyrocket After Success of Clinical Trial Announced

Reviva Pharmaceutical Holdings, Inc. (RVPH) stock prices were up a monumental 57.75% shortly after the trading day commenced on April 26th, 2021, bringing the price per share up to USD$6.72.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



What is RP5063?

This news came hot on the heels of the announcement of the full details for the results of RVPH’s Phase 2 clinical trial for RP5063 (brilaroxazine), its flagship drug candidate for the treatment of Acute Schizophrenia.

What does RP5063 do?


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


RP5063 has the potential to modulate and stabilize the D/5-HT system on account of its novel pharmacological profile against critical dopamine and serotonin receptors. The drug has exhibited exceptional capabilities that make it a frontrunner in competing treatments because of its potent affinity and surgical selectivity for the receptors it targets, which are implicated for schizophrenia and other comorbid symptoms.

RP5063 Phase 2 Clinical Trial

The Phase 2 trial aimed to assess the safety and efficacy of the drug in a randomized, double-blind, placebo-controlled, multicenter clinical study. 234 subjects with varying degrees of acute schizophrenic or schizoaffective disorders were given either RP5063 or a placebo, with the drug having met its primary endpoint. A statistically significant reduction by 20 in the total Positive and Negative Syndrome Scale (PANSS) when comparing reports from baseline with those of the placebo indicated massive success.

Resounding Success

All safety endpoints were met by RP5063, including clinical, prolactin, fasting glucose, EKG, body weight, labs, and lipids. The drug also improved cognition and the ability to function socially, while reducing both positive and negative symptoms. Should there be a positive outcome on a relevant endpoint in the pivotal third phase of the clinical study, the U.S. Food and Drug Administration has agreed to consider a potential “Superior Safety” label claim for the drug.

Scope of RP5063

With a massive scope of 3.5 million people affected by schizophrenia in the U.S. alone, and with no existing therapies that adequately address the complexities of the disorder, RP5063 has enormous potential. The drug also lacks the host of side effects associated with current antipsychotic treatments, which the company posits could lead to a reduction in discontinuation and non-compliance rates.

Future Outlook for RVPH

The implications of the success of Phase 2 trials are not lost on investors, evidenced by the huge surge in RVPH stock prices. With such an effective treatment for a disorder with as massive an unmet need as that of schizophrenia, RP5063 could dominate the space with its medical footprint. Current and prospective investors are hopeful for this to usher in significant and sustained increases in shareholder value.

Latest news

What is behind the fall of Torchlight Energy Resources Inc. (NASDAQ: TRCH) stock?

Torchlight Energy Resources, Inc. (NASDAQ: TRCH), a growth oil and gas exploration company specializing in the acquisition and development of highly profitable domestic oil...

Eros STX Global Corporation (ESGC) stock is declining: Here is the reason why?

Eros STX Global Corporation (NYSE ESGC) a global multinational media company that acquires, produces, and distributes films, television shows, and digital content issued its...

Yum China Holdings Inc. (YUMC): The Most Important Numbers You Should Know

Yum China Holdings Inc. (YUMC), which operates Taco Bell Restaurants, KFC Restaurants, and Pizza Hut Restaurants in China, has published its first-quarter report for...

Why shares of Akerna Corp. (KERN) stock are up today?

Akerna (KERN), a cannabis technology company focusing to connect data points in the global cannabis supply chain and developer of the cannabis industry's first...

Related news

What is behind the fall of Torchlight Energy Resources Inc. (NASDAQ: TRCH) stock?

Torchlight Energy Resources, Inc. (NASDAQ: TRCH), a growth oil and gas exploration company specializing in the acquisition and development of highly profitable domestic oil...

Eros STX Global Corporation (ESGC) stock is declining: Here is the reason why?

Eros STX Global Corporation (NYSE ESGC) a global multinational media company that acquires, produces, and distributes films, television shows, and digital content issued its...

Yum China Holdings Inc. (YUMC): The Most Important Numbers You Should Know

Yum China Holdings Inc. (YUMC), which operates Taco Bell Restaurants, KFC Restaurants, and Pizza Hut Restaurants in China, has published its first-quarter report for...

Why shares of Akerna Corp. (KERN) stock are up today?

Akerna (KERN), a cannabis technology company focusing to connect data points in the global cannabis supply chain and developer of the cannabis industry's first...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.